Abstract
Cytotoxic activity of four O,O'-dialkyl esters of ethylene-bis(S)-leucine [(S,S)-ethylenediamine-N,N’-di-2-(4- methyl)pentanoic acid] dihydrochlorides, R2edda-type esters L1.2HCl–L4.2HCl (alkyl = Et, n-Pr, n-Bu, and n-Pe, respectively), and corresponding palladium(II) (1–4) and platinum(II) (5–8) complexes against MDA-MB-361, MDA-MB-453 (human breast cancer), Jurkat (T-leukemia) and K562 (chronic myelogenous leukaemia) cell lines were determined. Results indicate cytotoxic potential of the investigated complexes based on induction of apoptosis.
Keywords: Palladium(II) complexes, Platinum(II) complexes, EDDA-type ligands, Human breast cancer, T-leukemia, Chronic myelogenous leukaemia.
Letters in Drug Design & Discovery
Title:In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Volume: 11 Issue: 4
Author(s): Jelena M. Vujic, Goran N. Kaluderovic, Tatjana P. Stanojkovic, Jadranka A. Antic and Srecko R. Trifunovic
Affiliation:
Keywords: Palladium(II) complexes, Platinum(II) complexes, EDDA-type ligands, Human breast cancer, T-leukemia, Chronic myelogenous leukaemia.
Abstract: Cytotoxic activity of four O,O'-dialkyl esters of ethylene-bis(S)-leucine [(S,S)-ethylenediamine-N,N’-di-2-(4- methyl)pentanoic acid] dihydrochlorides, R2edda-type esters L1.2HCl–L4.2HCl (alkyl = Et, n-Pr, n-Bu, and n-Pe, respectively), and corresponding palladium(II) (1–4) and platinum(II) (5–8) complexes against MDA-MB-361, MDA-MB-453 (human breast cancer), Jurkat (T-leukemia) and K562 (chronic myelogenous leukaemia) cell lines were determined. Results indicate cytotoxic potential of the investigated complexes based on induction of apoptosis.
Export Options
About this article
Cite this article as:
Vujic M. Jelena, Kaluderovic N. Goran, Stanojkovic P. Tatjana, Antic A. Jadranka and Trifunovic R. Srecko, In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine, Letters in Drug Design & Discovery 2014; 11 (4) . https://dx.doi.org/10.2174/15701808113106660092
DOI https://dx.doi.org/10.2174/15701808113106660092 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Copper-62 Labeled ReCCMSH Peptide Analogs for Melanoma PET Imaging
Current Radiopharmaceuticals Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery The Role of Vitamin D and Sunlight Incidence in Cancer
Anti-Cancer Agents in Medicinal Chemistry Organosulfur Compounds in Cancer Chemoprevention
Mini-Reviews in Medicinal Chemistry Scintigraphic Imaging of Inflammatory Processes
Medicinal Chemistry Reviews - Online (Discontinued) Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
Current Cancer Drug Targets Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Trace of Long Non-Coding RNAs in Signaling Pathways in Thyroid Cancer
Current Signal Transduction Therapy Positron Emission Tomography Radiopharmaceuticals for Sex Steroid Hormone Receptor Imaging
Current Medicinal Chemistry Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design Exosome Limitations in the Treatment of Inflammatory Diseases
Current Pharmaceutical Design Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Phytochemical and Biological Activities of an Anticancer Plant Medicine: Brucea javanica
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Hydrogen Sulfide: From Molecular Biology to Pharmacology Guest Editor: Stefano Fiorucci)]
Inflammation & Allergy - Drug Targets (Discontinued) How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design